Compare DexCom, Inc. (DXCM) vs USA Rare Earth Inc. Class A Common Stock (USAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs USA Rare Earth Inc. Class A Common Stock — how do they compare? DexCom, Inc. trades at $84.82 (market cap $32.09B), while USA Rare Earth Inc. Class A Common Stock trades at $10.13 (market cap $3.87B). The key difference: DexCom, Inc. is far larger — about 8.3× USA Rare Earth Inc. Class A Common Stock's market cap, and DexCom, Inc. is trading nearer its 52-week high, USA Rare Earth Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and USA Rare Earth Inc. Class A Common Stock for 0 Days on average.
| DXCM | USAR | |
|---|---|---|
Market Cap | $32.09B | $3.87B |
Volume | 3,819,730 | 20,993,390 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $33.68 |
52-Week Low | $54.84 | $10.32 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $31.54B | $2.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $85.06, down 1.0% on the day, with a bullish technical signal and strong fundamental growth. Revenue reached $4.66B in 2025 with a net income margin of 17.93%, and the company has beaten EPS estimates for the last three quarters. Recent news highlights expansion in Type 2 diabetes care and executive promotions, supporting positive sentiment.
The outlook is positive with a consensus price target of $96.14, implying 13% upside. Risks include competition and reimbursement challenges, but robust earnings growth and institutional backing provide a solid foundation for long-term investors.
USA Rare Earth (USAR) trades at $11.265, down 4.7% today and near its 52-week low, reflecting persistent sector pressure. The company shows severe financial strain with a net income margin of -2,159.3% and negative cash flow from operations, though analyst consensus remains unanimously bullish with a $34.57 price target. Recent news highlights strategic investments in a $1.2 billion South Carolina facility and a $2.8 billion Brazil acquisition to build a mine-to-magnet supply chain, positioning it for long-term growth amid U.S. critical mineral initiatives.
The stock presents high risk due to extreme losses and cash burn but offers speculative upside if government funding and project milestones materialize. Key risks include execution challenges, reliance on future financing, and sector volatility. Investors should weigh the bullish analyst outlook against the company's current financial instability and macroeconomic headwinds affecting rare earth markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About USA Rare Earth Inc. Class A Common Stock
USA Rare Earth is building an integrated rare earth and permanent magnet supply chain spanning mining, metal and alloy production, and magnet manufacturing, with assets including the Round Top heavy rare earth deposit in Texas, a magnet manufacturing facility in Stillwater, Oklahoma, and metal-and-alloy producer Less Common Metals.
Read more on USAR →
